Eosinophilic esophagitis clinical trials

Explore recruiting eosinophilic esophagitis clinical trials.

Recruiting eosinophilic esophagitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eosinophilic esophagitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in adult patients with eosinophilic esophagitis.

Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis

Germany, Portugal, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP 104GI in Adults with Eosinophilic Esophagitis (RESOLVE)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"

Italy, Germany, Austria, Portugal, Belgium, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eosinophilic esophagitis trials by city

Eosinophilic esophagitis in Toronto Eosinophilic esophagitis in Vancouver Eosinophilic esophagitis in Montreal Eosinophilic esophagitis in Calgary Eosinophilic esophagitis in Edmonton Eosinophilic esophagitis in Ottawa Eosinophilic esophagitis in Winnipeg Eosinophilic esophagitis in Quebec City Eosinophilic esophagitis in Hamilton Eosinophilic esophagitis in Kitchener Eosinophilic esophagitis in London Eosinophilic esophagitis in Halifax Eosinophilic esophagitis in New York Eosinophilic esophagitis in Los Angeles Eosinophilic esophagitis in Chicago Eosinophilic esophagitis in Houston

Other conditions

COPD Asthma Long COVID Cystic fibrosis Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Irritable bowel syndrome Celiac disease GERD Gastroparesis Rheumatoid arthritis Lupus Psoriatic arthritis Ankylosing spondylitis Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome Scleroderma Fibromyalgia Psoriasis